Compare GSK plc (GSK) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs New York Times Co — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while New York Times Co trades at $66.32 (market cap $10.74B). The key difference: GSK plc is far larger — about 8.6× New York Times Co's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and New York Times Co for 81 Days on average.
| GSK | NYT | |
|---|---|---|
Market Cap | $91.88B | $10.74B |
Volume | 7,730,529 | 2,096,352 |
Sector | Health | Media |
52-Week High | $61.18 | $85.86 |
52-Week Low | $43.24 | $54.66 |
Typical Hold Time | 93 Days | 81 Days |
Enterprise Value | $111.88B | $10.14B |
Dividend Yield | 3.9% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
The New York Times Company (NYT) trades at $66.60, up 2.62% today, reflecting strong momentum after three consecutive quarterly earnings beats. Revenue and net income have grown steadily from 2022 to 2025, with profit margins expanding to 12.17%. The stock shows a bullish technical signal overall, supported by positive cash flow trends and a declared quarterly dividend of $0.23 per share. However, a recent shareholder lawsuit alleging reporting bias introduces reputational risk.
Outlook remains positive given consistent earnings outperformance and a consensus price target of $84.00, implying significant upside. Key risks include the ongoing lawsuit, competitive pressures in digital media, and potential volatility from the AI copyright dispute with OpenAI. The company's solid fundamentals and analyst support suggest resilience, but investors should weigh legal and market challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
